Anti-Vascular Endothelial Growth Factor Therapeutics Market to Reach US$ 13.67 Bn by 2030

The global Anti-Vascular Endothelial Growth Factor Therapeutics market size is expected to reach USD 13.67 billion by 2030 and is expected to expand at a CAGR of 0.8% from 2021 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38607

Growth Factors

 The anti-Vascular Endothelial Growth Factor (VEGF) therapeutics market growth can be attributed to an increase in the prevalence of ophthalmic diseases, such as macular edema, diabetic retinopathy, retinal vein occlusion, and Age-related Macular Degeneration (AMD), coupled with an increasing geriatric population that is exposed to the risk of developing the condition. According to the WHO, around 196 million people are affected by AMD globally, which includes over 10.4 million cases with moderate to severe vision impairment. In addition, product launches and research advancements are contributing to the market growth.

Report Coverage

Report Scope Details
Market Size USD 14.80 billion by 2030
Growth Rate CAGR of 0.8% From 2021 to 2030
Base Year 2021
Historic Data 2017 to 2020
Forecast Period 2021 to 2030
Segments Covered Product, Disease
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Regeneron Pharmaceuticals, Inc.; Bayer AG; Novartis AG; F. Hoffmann-La Roche Ltd.; Biogen; Pfizer, Inc.; CoherusBioSciences; Amgen, Inc.; Bausch Health Companies, Inc.; and Viatris, Inc.

Report Highlights

The Eylea product segment dominated the global market in 2020 with a revenue share of over 68%. The segment is anticipated to retain its dominance throughout the forecast period. The product is expected to witness significant demand owing to advancements in formulations and the development of advanced drug delivery systems.

This new formulation may increase product adoption by ophthalmologists due to its ease of administration. Beovuis anticipated to witness the fastest CAGR over the forecast period owing to geographic expansion and patent exclusivity.

The Age-related Macular Degeneration (AMD) segment accounted for the largest market share of more than 89% in 2020.The segment is expected to maintain the leading position over the forecast period owing to the increasing disease burden, growing geriatric population, and presence of late-stage product candidates that are expected to enter the market in the coming years.

North America region accounted for the highest revenue share of more than 66% of the global market in 2020. The regional market is expected to witness a significant growth rate over the forecast period. Factors

Such delivery systems with technological advancements and product launches are expected to positively impact the market growth in the region. Asia Pacific is expected to grow at the fastest CAGR of 2.8% from2021 and 2030.

Key Players

  • F. Hoffmann-La Roche Ltd.
  • Biogen
  • Pfizer, Inc.
  • CoherusBioSciences
  • Amgen, Inc.
  • Bausch Health Companies, Inc.
  • Viatris, Inc.

Market Segmentation

  • Product
    • Eylea
    • Lucentis
    • Beovu
  • Disease
    • Macular Edema
    • Diabetic Retinopathy
    • Retinal Vein Occlusion
    • Age-related Macular Degeneration
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
    • Asia Pacific
      • India
      • China
      • Japan
      • Australia
    • Latin America
      • Argentina
      • Brazil
      • Mexico
    • Middle East & Africa
      • Saudi Arabia
      • UAE
      • South Africa

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38607

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, By Product

7.1.  Anti-Vascular Endothelial Growth Factor Therapeutics Market, by Product, 2021-2030

7.1.1.    Eylea

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Lucentis

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Beovu

7.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, By Disease

8.1.  Anti-Vascular Endothelial Growth Factor Therapeutics Market, by Disease, 2021-2030

8.1.1.    Macular Edema

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Diabetic Retinopathy

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Retinal Vein Occlusion

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Age-related Macular Degeneration

8.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.    Market Revenue and Forecast, by Product (2017-2030)

9.1.2.    Market Revenue and Forecast, by Disease (2017-2030)

9.1.3.    U.S.

9.1.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.1.3.2.        Market Revenue and Forecast, by Disease (2017-2030)

9.1.4.    Rest of North America

9.1.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.1.4.2.        Market Revenue and Forecast, by Disease (2017-2030)

9.2.  Europe

9.2.1.    Market Revenue and Forecast, by Product (2017-2030)

9.2.2.    Market Revenue and Forecast, by Disease (2017-2030)

9.2.3.    UK

9.2.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.2.3.2.        Market Revenue and Forecast, by Disease (2017-2030)

9.2.4.    Germany

9.2.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.2.4.2.        Market Revenue and Forecast, by Disease (2017-2030)

9.2.5.    France

9.2.5.1.        Market Revenue and Forecast, by Product (2017-2030)

9.2.5.2.        Market Revenue and Forecast, by Disease (2017-2030)

9.2.6.    Rest of Europe

9.2.6.1.        Market Revenue and Forecast, by Product (2017-2030)

9.2.6.2.        Market Revenue and Forecast, by Disease (2017-2030)

9.3.  APAC

9.3.1.    Market Revenue and Forecast, by Product (2017-2030)

9.3.2.    Market Revenue and Forecast, by Disease (2017-2030)

9.3.3.    India

9.3.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.3.3.2.        Market Revenue and Forecast, by Disease (2017-2030)

9.3.4.    China

9.3.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.3.4.2.        Market Revenue and Forecast, by Disease (2017-2030)

9.3.5.    Japan

9.3.5.1.        Market Revenue and Forecast, by Product (2017-2030)

9.3.5.2.        Market Revenue and Forecast, by Disease (2017-2030)

9.3.6.    Rest of APAC

9.3.6.1.        Market Revenue and Forecast, by Product (2017-2030)

9.3.6.2.        Market Revenue and Forecast, by Disease (2017-2030)

9.4.  MEA

9.4.1.    Market Revenue and Forecast, by Product (2017-2030)

9.4.2.    Market Revenue and Forecast, by Disease (2017-2030)

9.4.3.    GCC

9.4.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.4.3.2.        Market Revenue and Forecast, by Disease (2017-2030)

9.4.4.    North Africa

9.4.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.4.4.2.        Market Revenue and Forecast, by Disease (2017-2030)

9.4.5.    South Africa

9.4.5.1.        Market Revenue and Forecast, by Product (2017-2030)

9.4.5.2.        Market Revenue and Forecast, by Disease (2017-2030)

9.4.6.    Rest of MEA

9.4.6.1.        Market Revenue and Forecast, by Product (2017-2030)

9.4.6.2.        Market Revenue and Forecast, by Disease (2017-2030)

9.5.  Latin America

9.5.1.    Market Revenue and Forecast, by Product (2017-2030)

9.5.2.    Market Revenue and Forecast, by Disease (2017-2030)

9.5.3.    Brazil

9.5.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.5.3.2.        Market Revenue and Forecast, by Disease (2017-2030)

9.5.4.    Rest of LATAM

9.5.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.5.4.2.        Market Revenue and Forecast, by Disease (2017-2030)

Chapter 10.  Company Profiles

10.1.              F. Hoffmann-La Roche Ltd.

10.1.1.  Company Overview

10.1.2.  Product Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.              Biogen

10.2.1.  Company Overview

10.2.2.  Product Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.              Pfizer, Inc.

10.3.1.  Company Overview

10.3.2.  Product Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.              CoherusBioSciences

10.4.1.  Company Overview

10.4.2.  Product Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.              Syner-Med (Pharmaceutical Products) Ltd.

10.5.1.  Company Overview

10.5.2.  Product Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.              Amgen, Inc.

10.6.1.  Company Overview

10.6.2.  Product Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.              Bausch Health Companies, Inc.

10.7.1.  Company Overview

10.7.2.  Product Offerings

10.7.3.  Financial Performance

10.7.4.  Recent Initiatives

10.8.              Viatris, Inc.

10.8.1.  Company Overview

10.8.2.  Product Offerings

10.8.3.  Financial Performance

10.8.4.  Recent Initiatives

Chapter 11.  Research Methodology

11.1.              Primary Research

11.2.              Secondary Research

11.3.              Assumptions

Chapter 12.  Appendix

12.1.              About Us

Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38607

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com